PALI · Insider Trading
Palisade Bio, Inc. Common Stock
Every open-market purchase and sale reported by PALI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Julien E. Capers | See Remarks | A | +787,300 | — |
| 2026-10-07 | Mitchell Lawrence Jones | See Remarks | MIXED | +1,589,748 | −$1.54M |
| 2026-10-07 | John David Finley | CEO CFO | MIXED | +1,815,402 | −$2.10M |
| 2026-10-05 | Donald Allen Williams | Director | Buy | +20,000 | +$28.80K |
| 2026-08-21 | John David Finley | CEO, CFO | G | — | — |
| 2026-07-10 | Robert Baltera Jr. | Director | Buy | +45,000 | +$88.70K |
| 2026-07-08 | Robert Baltera Jr. | Director | Buy | +50,000 | +$102.08K |
| 2026-07-08 | John David Finley | CEO, CFO | MIXED | +188,502 | −$303.25K |
| 2026-07-08 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | +79,287 | −$106.54K |
| 2026-07-06 | Robert Baltera Jr. | Director | Buy | +30,000 | +$59.40K |
| 2026-06-18 | Robert Baltera Jr. | Director | A | +336,904 | — |
| 2026-06-12 | Jordan Michael Zwick | Director | A | +336,904 | — |
| 2026-06-12 | Donald Allen Williams | Director | MIXED | +1,559,566 | — |
| 2026-06-12 | Binxian Wei | Director | MIXED | +612,500 | — |
| 2026-06-12 | Emil Chuang | Director | MIXED | +612,500 | — |
| 2026-02-13 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | +6,011 | −$3.48K |
| 2026-02-13 | John David Finley | CEO, CFO | MIXED | +9,437 | −$6.82K |
| 2026-02-11 | Mitchell Lawrence Jones | Chief Medical Officer | A | +787,000 deriv. | — |
| 2026-02-11 | John David Finley | CEO, CFO | A | +2,011,000 deriv. | — |
| 2026-01-21 | Donald Allen Williams | Director | Buy | +5,000 | +$8.36K |
| 2026-01-13 | Donald Allen Williams | Director | Buy | +5,000 | +$9.40K |
| 2025-11-06 | Emil Chuang | Director | A | +60,600 deriv. | — |
| 2025-11-06 | Binxian Wei | Director | A | +60,600 deriv. | — |
| 2025-11-06 | Donald Allen Williams | Director | A | +182,000 deriv. | — |
| 2025-10-08 | Emil Chuang | Director | A | +510,700 deriv. | — |
| 2025-10-08 | Donald Allen Williams | Director | A | +1,538,700 deriv. | — |
| 2025-10-08 | Mitchell Lawrence Jones | Chief Medical Officer | A | +7,665,800 deriv. | — |
| 2025-10-08 | John David Finley | CEO, CFO | A | +9,179,400 deriv. | — |
| 2025-10-08 | Binxian Wei | Director | A | +510,700 deriv. | — |
| 2025-09-05 | Donald Allen Williams | Director | A | +64,400 deriv. | — |
| 2025-09-05 | John David Finley | CEO, CFO | A | +323,400 deriv. | — |
| 2025-09-05 | Binxian Wei | Director | A | +18,800 deriv. | — |
| 2025-09-05 | Emil Chuang | Director | A | +18,800 deriv. | — |
| 2025-09-05 | Mitchell Lawrence Jones | Chief Medical Officer | A | +289,000 deriv. | — |
| 2025-07-22 | Emil Chuang | Director | A | +8,000 deriv. | — |
| 2025-02-13 | Mitchell Lawrence Jones | Chief Medical Officer | A | +53,000 deriv. | — |
| 2025-02-13 | John David Finley | CEO, CFO | A | +87,000 deriv. | — |
| 2024-11-22 | Binxian Wei | Director | M | +388 | — |
| 2024-11-22 | Donald Allen Williams | Director | M | +388 | — |
| 2024-07-15 | Binxian Wei | Director | A | +2,100 deriv. | — |
| 2024-07-15 | Donald Allen Williams | Director | A | +2,100 deriv. | — |
| 2024-07-15 | Margery B. Fischbein | Director | A | +2,100 deriv. | — |
| 2024-06-12 | Binxian Wei | Director | M | +465 | — |
| 2024-06-12 | Donald Allen Williams | Director | M | +340 | — |
| 2024-05-30 | Mitchell Lawrence Jones | Chief Medical Officer | MIXED | +3,019 | −$6.05K |
| 2024-05-30 | John David Finley | CEO, CFO, Director | MIXED | +5,035 | −$9.68K |
| 2024-05-29 | Donald Allen Williams | Director | Buy | +1,000 | +$4.86K |
| 2024-05-28 | John David Finley | CEO, CFO, Director | Buy | +1,000 | +$4.81K |
| 2024-05-22 | John David Finley | CEO, CFO, Director | A | +666 | +$3.31K |
| 2024-05-08 | John David Finley | CEO, CFO, Director | MIXED | +315 | −$1.08K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Mitchell Lawrence Jones | See Remarks | 2,714,859 | $3.34M |
| John David Finley | CEO CFO | 2,033,141 | $2.50M |
| Donald Allen Williams | Director | 1,583,294 | $1.95M |
| Julien E. Capers | See Remarks | 787,300 | $968.38K |
| Binxian Wei | Director | 613,355 | $754.43K |
| Emil Chuang | Director | 612,500 | $753.38K |
| Robert Baltera Jr. | Director | 461,904 | $568.14K |
| Jordan Michael Zwick | Director | 336,904 | $414.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PALI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.